Physician profile
Andres E Huberman
NPI 1063579043
$7,208.20
in general payments reported to CMS, 2019-2025
17 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 85% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $401 · 2021: $721 · 2022: $1,164 · 2023: $1,503 · 2024: $1,174 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.85 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,455.88 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $1,206.32 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,173.19 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $527.12 | 2020-2025 | Trintellix |
| Axsome Therapeutics, INC. | $479.37 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $470.16 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $423.01 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $295.65 | 2019-2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $243.03 | 2024 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $222.76 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $207.05 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.31 | 2022-2024 | Caplyta |
| Alkermes, INC. | $131.68 | 2023 | Aristada, Aristada Initio, Lybalvi |
| Allergan, INC. | $125.09 | 2020 | |
| Merck Sharp & Dohme LLC | $66.55 | 2021-2023 | Belsomra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.28 | 2022 | |
| Bausch Health US, LLC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Huberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.